zidovudine has been researched along with foscarnet in 98 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 21 (21.43) | 18.7374 |
1990's | 48 (48.98) | 18.2507 |
2000's | 21 (21.43) | 29.6817 |
2010's | 8 (8.16) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Corbett, TH; Court, BA; Kessel, D; Phadtare, S; Renis, HE; Zimlicka, J | 1 |
De Clercq, E | 1 |
Fu, H; Hostetler, KY; Mellors, J; Pai, N; Richman, DD; Rosowsky, A | 1 |
Cha, SH; Endou, H; Kanai, Y; Kimura, M; Sekine, T; Tsuda, M; Wada, S | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Chen, JJ; Cheng, P; Jiang, ZY; Wang, Q; Wang, RR; Zhang, XM; Zheng, YT; Zhou, J | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Campillo, NE; Guerra, A; Páez, JA | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Endo, T; Higuchi, H; Kaji, A; Kaji, H; Kato, A; Matsumoto, H; Mochida, S; Ogata, T | 1 |
Skolnik, PR | 1 |
Connolly, S; Malin, A; Manji, H | 1 |
Causey, DM; Davis, RB; Grieco, MH; Hooton, TM; Jacobson, MA; McKinley, GF; Parenti, DM; Reddy, MM; van der Horst, CM | 1 |
Morris, DJ | 2 |
Cheng, YC; Dutschman, GE; Im, GJ; Mellors, JW; Tramontano, E; Winkler, SR | 1 |
Cheng, YC; Tramontano, E | 1 |
Burrell, CJ; Kuiper, LJ; Li, P; Stephenson, AJ | 1 |
Aweeka, FT; Gambertoglio, JG; Jacobson, MA; Raasch, R; van der Horst, C | 1 |
Seigneurin, JM | 1 |
Cox, SW; Wahren, B | 1 |
Anderson, S; Beck, EJ; Coker, R; Coleman, D; Harris, JR; Main, J; Migdal, C; Peters, BS; Pinching, AJ | 1 |
Ayisi, NK; Gupta, SV; Qualtiere, LF | 1 |
Kemp, SD; Larder, BA; Lowe, DM; Parmar, V | 1 |
Quan, K; Tao, P; Zhang, X | 1 |
Cox, S; Harmenberg, J; Koshida, R; Wahren, B | 1 |
Armstrong, D; Chou, TC; Gold, JW; Kong, XB; Polsky, B; Ruprecht, RM; Watanabe, KA; Zeidler, JM; Zhu, QY | 1 |
Cersosimo, RJ; Matthews, SJ; Spivack, ML | 1 |
Causey, DM; Dehlinger, M; Hafner, R; Jacobsen, MA; Mills, J; van der Horst, C | 1 |
Aubertin, P; Barrier, JH; Boibieux, A; Lortholary, A; Peyramond, D; Raffi, F | 1 |
Balzarini, J; Bron, D; De Clercq, E; Delforge, A; Lagneaux, L; Snoeck, R; Stryckmans, P; Van der Auwera, P | 1 |
Hirsch, MS; Schooley, RT; Vogt, M | 1 |
Pomerantz, RJ; Schooley, RT | 1 |
Bryson, YJ | 1 |
Darby, G; Larder, BA; Richman, DD | 1 |
Mitchell, WM; Montefiori, DC; Robinson, WE | 1 |
Kemp, SD; Larder, BA; Purifoy, DJ | 1 |
Kurth, R; Löwer, J; Oberg, B; Vrang, L | 1 |
Gilljam, G; Harmenberg, J; Koshida, R; Oberg, B; Vrang, L; Wahren, B | 1 |
Crowe, SM; Elbeik, T; Kirihara, J; McGrath, MS; Mills, J | 1 |
Cox, S; Gilljam, G; Harmenberg, J; Koshida, R; Wahren, B | 1 |
Jacobson, MA; O'Donnell, JJ | 1 |
Girard, B; Katlama, C; Lehoang, P; Lernestedt, JO; Marcel, P; Matheron, S; Morer, I; Robinet, M; Rozenbaum, W; Zazoun, L | 1 |
Eriksson, BF; Schinazi, RF | 1 |
Kaplan, JC; Sandström, EG | 1 |
Broder, S; Yarchoan, R | 1 |
Wyngaarden, JB | 1 |
Richman, DD | 1 |
Collins, P; Evans, R; Hawkins, DA; Lawrence, A; Oliver, N; Shanson, DC; Youle, MM | 1 |
Sandström, E | 1 |
Weber, J | 1 |
Cheng, YC; Gonzalez, CJ; Im, GJ; Tramontano, E | 1 |
Birch, C; Hoy, J; McGavin, K; Tachedjian, G | 1 |
Caliendo, AM; Hirsch, MS | 1 |
Blay, RA; Buck, SM; Epstein, JS; Geyer, S; Mayner, RE; Pollock, L; Selvam, MP | 1 |
Fleckenstein, B; Stamminger, T | 1 |
Gobert, JM; North, TW; Remington, KM; Zhu, YQ | 1 |
Brun-Vezinet, F; Pépin, JM; Simon, F | 1 |
Baird, BF; Davey, RT; deSmet, MD; Falloon, J; Kovacs, JA; Masur, H; Mellow, S; Nussenblatt, RB; Palestine, AG; Polis, MA | 1 |
Blackburn, EH; Strahl, C | 1 |
Anderson, KP; Azad, RF; Brown-Driver, V; Buckheit, RW | 1 |
Detels, RR; Hoover, DR; Peng, Y; Phair, JP; Rinaldo, CR; Saah, A; Semba, R | 1 |
Cox, S; Harmenberg, J; Palmer, S | 1 |
Bazmi, H; Birch, C; Mellors, J; Mills, J; Tachedjian, G | 1 |
Beauchamp, D; Bergeron, MG; Désormeaux, A; Gourde, P; Omar, RF; Tremblay, M | 1 |
Brisson, E; Guettari, N; Klatzmann, D; Loubière, L | 1 |
Alaeus, A; Albert, J; Cox, S; Palmer, S | 1 |
Andreula, CF; Angarano, G; Appice, A; Di Stefano, M; Fiore, JR; Monno, L; Pastore, G; Perulli, LM; Zimatore, GB | 1 |
French, M; Mills, J; Tachedjian, G | 1 |
Arion, D; Borkow, G; Kaushik, N; McCormick, S; Parniak, MA | 1 |
Aubertin, AM; de Monte, M; Faraj, A; Gosselin, G; Imbach, JL; Meier, C; Périgaud, C; Sommadossi, JP | 1 |
Bazmi, HZ; La Colla, P; Mellors, JW; Piras, G; Putzolu, M; Tramontano, E | 1 |
Bareta, J; Hidalgo, J; Rhee, W; Steidl, S; Wutoh, AK | 1 |
Arion, D; Parniak, MA; Sluis-Cremer, N | 1 |
Aldern, KA; Beadle, JR; Chou, TC; Hammond, JL; Hostetler, KY; Hostetler, SE; Kini, GD; Mellors, JW; Richman, DD | 1 |
Boretto, J; Canard, B; Capony, JP; Lazaro, JB; Selmi, B | 1 |
Aldern, KA; Bazmi, HZ; Beadle, JR; Hammond, JL; Hostetler, KY; Hostetler, SE; Kini, GD; Koontz, DL; Mellors, JW; Richman, DD | 1 |
Gérard, M; Hainaut, M; Levy, J; Mascart, F; Peltier, CA; Souayah, H; Zissis, G | 1 |
Bazmi, HZ; Chopra, RR; Matsuura, SE; Mellors, JW; Meyer, PR; Pendarvis, E; Scott, WA; Zonarich, D | 1 |
Goldschmidt, V; Marquet, R | 1 |
Bocharov, EV; Fedyuk, NV; Ivanov, AV; Jasko, MV; Khandazhinskaya, AL; Kukhanova, MK; Mitkevich, VA; Pokrovsky, AG; Pronyaeva, TR; Shirokova, EA; Skoblov, YS; Yanvarev, DV | 1 |
Feuston, B; Getty, K; Hazuda, DJ; Krueger, J; Lewis, D; Miller, MD; Munshi, V; Parniak, MA; Shaw-Reid, CA | 1 |
Anderson, DJ; Preston, BD; Smith, RA | 1 |
Ansó, E; Cruchaga, C; Martínez-Irujo, JJ; Rouzaut, A | 1 |
Clavel, F; Dam, E; Gerstoft, J; Joergensen, LB; Laursen, AL; Mathiesen, S; Roge, B | 1 |
Kisic, M; Martínez, MA; Martinez-Picado, J; Mendieta, J; Menéndez-Arias, L; Parera, M; Puertas, MC | 1 |
Bélec, L; Charpentier, C; Karmochkine, M; Laureillard, D; Piketty, C; Si-Mohamed, A; Sodqi, M; Weiss, L | 1 |
Hamprecht, K; Schott, H; Schott, S; Schott, TC; Schwendener, RA | 1 |
Tan, DH; Walmsley, SL | 1 |
Arastéh, K; Dieckmann, S; Drauz, D; Grueneisen, A; Koch, A; Marretta, L; Masuhr, A; Mueller, M; Stocker, H; Weiss, R; Wong, V | 1 |
Agut, H; Caumes, E; Challine, D; Deback, C; Lascaux, AS; Lévy, Y; Melica, G | 1 |
Auge-Courtoi, C; Charpentier, C; Delory, T; Descamps, D; Matheron, S; Michard, F; Papot, E; Peytavin, G; Rioux, C; Yazdanpanah, Y | 1 |
15 review(s) available for zidovudine and foscarnet
Article | Year |
---|---|
Chemotherapeutic approaches to the treatment of the acquired immune deficiency syndrome (AIDS).
Topics: Acquired Immunodeficiency Syndrome; Adsorption; Antibodies, Viral; Antigens, Viral; Aurintricarboxylic Acid; Deltaretrovirus; Deoxycytidine; Foscarnet; Genes, Viral; Glycoproteins; Humans; Interferons; Male; Phosphonoacetic Acid; Retroviridae Infections; Reverse Transcriptase Inhibitors; Ribavirin; RNA, Viral; Suramin; Thymidine; Transcription, Genetic; Viral Proteins; Virus Replication; Zalcitabine; Zidovudine | 1986 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Child; Didanosine; Female; Foscarnet; HIV Infections; Humans; Phosphonoacetic Acid; Pregnancy; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1991 |
Therapy of human immunodeficiency virus infections.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Foscarnet; Humans; Immunotherapy; Interferons; Oligodeoxyribonucleotides; Phosphonoacetic Acid; Ribavirin; Suramin; Thymidine; Zidovudine | 1987 |
Promising new antiviral drugs.
Topics: Acyclovir; Animals; Antiviral Agents; Bromodeoxyuridine; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Herpes Simplex; Herpes Zoster; Humans; Interferons; Phosphonoacetic Acid; Ribavirin; Thymidine; Zidovudine | 1988 |
Cotton-wool spots and cytomegalovirus retinitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Cytomegalovirus Infections; Diabetic Retinopathy; Diagnosis, Differential; Foscarnet; Ganciclovir; Humans; Phosphonoacetic Acid; Pneumonia, Pneumocystis; Prognosis; Retinal Diseases; Retinitis; Zidovudine | 1989 |
Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date.
Topics: Acquired Immunodeficiency Syndrome; Antimony; Antiviral Agents; Forecasting; Foscarnet; Immunotherapy; Phosphonoacetic Acid; Rifabutin; Rifamycins; Suramin; Thymidine; Tungsten; Tungsten Compounds; Zidovudine | 1987 |
Progress in the development of antiviral therapy for HTLV-III-associated diseases.
Topics: Acquired Immunodeficiency Syndrome; Antimony; Antiviral Agents; Foscarnet; HIV; Humans; Phosphonoacetic Acid; Ribavirin; Rifabutin; Rifamycins; Suramin; Thymidine; Tungsten; Tungsten Compounds; Zidovudine | 1987 |
The treatment of HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Dideoxynucleosides; Drug Evaluation; Foscarnet; Humans; Opportunistic Infections; Phosphonoacetic Acid; Zalcitabine; Zidovudine | 1988 |
Antiviral drugs for AIDS. Current status and future prospects.
Topics: Acquired Immunodeficiency Syndrome; Antimony; Antiviral Agents; Foscarnet; Humans; Interferon Type I; Phosphonoacetic Acid; Ribavirin; Suramin; Thymidine; Tungsten; Tungsten Compounds; Zidovudine | 1986 |
Combination therapy for infection due to human immunodeficiency virus type 1.
Topics: Acyclovir; Antiviral Agents; CD4 Antigens; Clinical Trials as Topic; Combined Modality Therapy; Didanosine; Drug Therapy, Combination; Foscarnet; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; In Vitro Techniques; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1994 |
Adverse effects and drug interactions of clinical importance with antiviral drugs.
Topics: Acyclovir; AIDS-Related Opportunistic Infections; Amantadine; Antiviral Agents; Didanosine; Drug Interactions; Foscarnet; Ganciclovir; Humans; Interferon-alpha; Ribavirin; Rimantadine; Vidarabine; Zalcitabine; Zidovudine | 1994 |
[Is resistance of human immunodeficiency viruses (HIV) to nucleoside analogs an indication for their combined use?].
Topics: Acyclovir; Didanosine; Drug Synergism; Drug Therapy, Combination; Female; Foscarnet; HIV-1; Humans; In Vitro Techniques; Male; Ribavirin; Zalcitabine; Zidovudine | 1993 |
Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet).
Topics: Acquired Immunodeficiency Syndrome; Cohort Studies; Cytomegalovirus Infections; Didanosine; Drug Tolerance; Follow-Up Studies; Foscarnet; Ganciclovir; Humans; Infusions, Intravenous; Injections, Intravenous; Retinitis; Survival Rate; Time Factors; Zidovudine | 1993 |
Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs).
Topics: Adenosine Triphosphate; DNA Primers; Drug Resistance, Multiple, Viral; Foscarnet; HIV; HIV Reverse Transcriptase; Humans; Point Mutation; Reverse Transcriptase Inhibitors; Thymidine; Zidovudine | 2004 |
6 trial(s) available for zidovudine and foscarnet
Article | Year |
---|---|
Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cytomegalovirus Infections; Dose-Response Relationship, Drug; Drug Evaluation; Foscarnet; HIV Core Protein p24; Humans; Middle Aged; Phosphonoacetic Acid; Retinitis; Zidovudine | 1992 |
Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Cytomegalovirus Infections; Drug Therapy, Combination; Drug Tolerance; Foscarnet; Ganciclovir; Humans; Leukocyte Count; Phosphonoacetic Acid; Random Allocation; Retinitis; Zidovudine | 1992 |
[Chemotherapy and immunoprophylaxis of HIV infection].
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Foscarnet; HIV; Humans; Phosphonoacetic Acid; Reverse Transcriptase Inhibitors; Ribavirin; Suramin; Thymidine; Viral Vaccines; Virus Replication; Zidovudine | 1986 |
From the National Institutes of Health. Progress in AIDS research.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infections; Drug Therapy, Combination; Foscarnet; Humans; Interferon Type I; Phosphonoacetic Acid; Recombinant Proteins; Research; Vaccines; Zidovudine | 1988 |
The treatment of HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Dideoxynucleosides; Drug Evaluation; Foscarnet; Humans; Opportunistic Infections; Phosphonoacetic Acid; Zalcitabine; Zidovudine | 1988 |
Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet).
Topics: Acquired Immunodeficiency Syndrome; Cohort Studies; Cytomegalovirus Infections; Didanosine; Drug Tolerance; Follow-Up Studies; Foscarnet; Ganciclovir; Humans; Infusions, Intravenous; Injections, Intravenous; Retinitis; Survival Rate; Time Factors; Zidovudine | 1993 |
79 other study(ies) available for zidovudine and foscarnet
Article | Year |
---|---|
Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.
Topics: Adenosine Deaminase; Animals; Antimetabolites, Antineoplastic; Antiviral Agents; Cell Line; Cell Survival; Drug Screening Assays, Antitumor; Friend murine leukemia virus; HIV-1; HIV-2; Humans; Indicators and Reagents; Leukemia L1210; Mice; Molecular Structure; Nucleosides; Rauscher Virus; Structure-Activity Relationship | 1991 |
Synthesis and in vitro activity of long-chain 5'-O-[(alkoxycarbonyl)phosphinyl]-3'-azido-3'-deoxythymidines against wild-type and AZT- and foscarnet-resistant strains of HIV-1.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cell Line; Drug Combinations; Drug Resistance, Microbial; Foscarnet; HIV-1; Humans; Magnetic Resonance Spectroscopy; Models, Chemical; Mutagenesis, Site-Directed; Prodrugs; Virus Replication; Zidovudine | 1997 |
Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs.
Topics: Acyclovir; Animals; Anion Transport Proteins; Antiviral Agents; Carrier Proteins; Didanosine; In Vitro Techniques; Lamivudine; Oocytes; Rats; Stavudine; Transfection; Trifluridine; Xenopus laevis; Zalcitabine; Zidovudine | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Synthesis and biological evaluation of N-acetyl-beta-aryl-1,2-didehydroethylamines as new HIV-1 RT inhibitors in vitro.
Topics: Ethylamines; HIV Reverse Transcriptase; HIV-1; Molecular Structure; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
HIV-1 reverse transcriptase inhibitor from Phyllanthus niruri.
Topics: Antigens, Viral; Benzopyrans; Binding, Competitive; Cell Fusion; Chromatography; DNA-Directed DNA Polymerase; Dose-Response Relationship, Drug; Ellagic Acid; Foscarnet; Gallic Acid; Glucose; HIV Core Protein p24; HIV Reverse Transcriptase; HIV-1; Plant Extracts; Plants; Reverse Transcriptase Inhibitors; Zidovudine | 1992 |
Treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Drug Therapy, Combination; Foscarnet; Ganciclovir; Humans; Phosphonoacetic Acid; Retinitis; Zidovudine | 1992 |
CMV polyradiculopathy in AIDS--suggestions for new strategies in treatment.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cytomegalovirus Infections; Foscarnet; Humans; Male; Nervous System Diseases; Phosphonoacetic Acid; Zidovudine | 1992 |
Treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Viral; Foscarnet; Ganciclovir; Humans; Phosphonoacetic Acid; Retinitis; Zidovudine | 1992 |
In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase.
Topics: Antiviral Agents; Base Sequence; Benzodiazepines; CD4-Positive T-Lymphocytes; Cloning, Molecular; Drug Resistance, Microbial; Foscarnet; Gene Expression; HeLa Cells; HIV-1; Humans; Imidazoles; Molecular Sequence Data; Nevirapine; Phosphonoacetic Acid; Polymerase Chain Reaction; Pyridines; Recombinant Proteins; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Zidovudine | 1992 |
HIV-1 reverse transcriptase inhibition by a dipyridodiazepinone derivative: BI-RG-587.
Topics: Antiviral Agents; Foscarnet; HIV-1; Kinetics; Nevirapine; Phosphonoacetic Acid; Pyridines; Reverse Transcriptase Inhibitors; Templates, Genetic; Zidovudine | 1992 |
De novo reverse transcription is a crucial event in cell-to-cell transmission of human immunodeficiency virus.
Topics: Antiviral Agents; DNA, Viral; Foscarnet; HIV Reverse Transcriptase; HIV-1; Humans; Middle Aged; Phosphonoacetic Acid; RNA-Directed DNA Polymerase; Virus Replication; Zidovudine | 1992 |
Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053).
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Chromatography, High Pressure Liquid; Drug Interactions; Foscarnet; HIV Core Protein p24; Humans; Male; Middle Aged; Zidovudine | 1992 |
[Resistance of viruses to antiviral agents].
Topics: Acyclovir; Antiviral Agents; Drug Resistance; Foscarnet; Humans; Immunocompromised Host; Phosphonoacetic Acid; Rimantadine; Virus Diseases; Zidovudine | 1992 |
Treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Synergism; Drug Therapy, Combination; Foscarnet; Ganciclovir; Humans; Phosphonoacetic Acid; Zidovudine | 1992 |
Cytomegalovirus infection in AIDS. Patterns of disease, response to therapy and trends in survival.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Colitis; Cytomegalovirus Infections; Female; Foscarnet; Ganciclovir; Humans; London; Male; Neutropenia; Opportunistic Infections; Phosphonoacetic Acid; Prevalence; Recurrence; Retinitis; Retrospective Studies; Survival Rate; Thrombocytopenia; Zidovudine | 1991 |
Modified tetrazolium-based colorimetric method for determining the activities of anti-HIV compounds.
Topics: Antiviral Agents; Cell Line; Colorimetry; Didanosine; Foscarnet; HIV-1; Humans; Phosphonoacetic Acid; Tetrazolium Salts; Thymidine; Zalcitabine; Zidovudine | 1991 |
Mutational analysis of two conserved sequence motifs in HIV-1 reverse transcriptase.
Topics: Amino Acid Sequence; Dideoxynucleotides; DNA Mutational Analysis; Foscarnet; HIV-1; In Vitro Techniques; Kinetics; Molecular Sequence Data; Phosphonoacetic Acid; Recombinant Proteins; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Structure-Activity Relationship; Thymine Nucleotides; Zidovudine | 1991 |
The characterization of EIAV reverse transcriptase and its inhibition by 5'-triphosphates of 2'-deoxyuridine analogs, PFA and PAA.
Topics: Antiviral Agents; Dideoxynucleotides; Foscarnet; HIV; Infectious Anemia Virus, Equine; Phosphonoacetic Acid; RNA-Directed DNA Polymerase; Thymine Nucleotides; Zidovudine | 1990 |
Synergistic combinations and peptides in the inhibition of human immunodeficiency virus.
Topics: Alpha-Globulins; Amino Acid Sequence; Antiviral Agents; Cell Line; Dideoxynucleosides; Drug Synergism; Foscarnet; HIV; Humans; Molecular Sequence Data; Oligopeptides; Phosphonoacetic Acid; Proteins; Reverse Transcriptase Inhibitors; Serine Proteinase Inhibitors; Virus Replication; Zidovudine | 1991 |
Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3'-azido-3'-deoxythymidine, phosphonoformate, and 2',3'-dideoxythymidine.
Topics: Antiviral Agents; Cell Line; Cell Survival; Cell-Free System; Dideoxynucleosides; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Foscarnet; HIV-1; Humans; Phosphonoacetic Acid; Reverse Transcriptase Inhibitors; Virus Replication; Zidovudine | 1991 |
In vivo additive antiretroviral effect of combined zidovudine and foscarnet therapy for human immunodeficiency virus infection (ACTG Protocol 053).
Topics: Administration, Oral; Antiviral Agents; Drug Therapy, Combination; Follow-Up Studies; Foscarnet; Gene Products, gag; HIV Antigens; HIV Core Protein p24; HIV Infections; Humans; Infusions, Intravenous; Phosphonoacetic Acid; Viral Core Proteins; Zidovudine | 1991 |
HIV-associated haemophagocytic syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Bacterial Agents; Antiviral Agents; Drug Therapy, Combination; Foscarnet; Histiocytosis, Non-Langerhans-Cell; Humans; Male; Phosphonoacetic Acid; Zidovudine | 1990 |
Inhibitory effects of potent inhibitors of human immunodeficiency virus and cytomegalovirus on the growth of human granulocyte-macrophage progenitor cells in vitro.
Topics: Adenine; Adult; Antiviral Agents; Bone Marrow; Bone Marrow Cells; Cells, Cultured; Cidofovir; Cytomegalovirus; Cytosine; Foscarnet; Ganciclovir; Granulocytes; Hematopoietic Stem Cells; HIV; Humans; Macrophages; Organophosphonates; Organophosphorus Compounds; Phosphonoacetic Acid; Zidovudine | 1990 |
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Dideoxynucleosides; Drug Resistance; Foscarnet; HeLa Cells; HIV; HIV Core Protein p24; Humans; Microbial Sensitivity Tests; Phosphonoacetic Acid; Retroviridae Proteins; Reverse Transcriptase Inhibitors; Viral Plaque Assay; Virus Replication; Zalcitabine; Zidovudine | 1989 |
In vitro evaluation of mismatched double-stranded RNA (ampligen) for combination therapy in the treatment of acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Alkaloids; Amphotericin B; Antiviral Agents; Drug Therapy, Combination; Foscarnet; HIV; Humans; In Vitro Techniques; Indolizines; Interferon beta-1a; Interferon beta-1b; Interferon Type I; Interferon-beta; Interferon-gamma; Interferons; Microbial Sensitivity Tests; Phosphonoacetic Acid; Recombinant Proteins; Ribavirin; RNA, Double-Stranded; Zidovudine | 1989 |
Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity.
Topics: Amino Acid Sequence; Antiviral Agents; Cell Line; Cloning, Molecular; Escherichia coli; Foscarnet; Genes; Genes, Viral; HIV-1; Humans; Molecular Sequence Data; Mutation; Phosphonoacetic Acid; Recombinant Proteins; RNA-Directed DNA Polymerase; Transfection; Zidovudine | 1989 |
Reverse transcriptases from human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus (SIVMAC) are susceptible to inhibition by foscarnet and 3'-azido-3'-deoxythymidine triphosphate.
Topics: Animals; Dideoxynucleotides; Foscarnet; HIV-1; HIV-2; Humans; Organophosphorus Compounds; Phosphonoacetic Acid; Reverse Transcriptase Inhibitors; Simian Immunodeficiency Virus; Thymine Nucleotides; Zidovudine | 1988 |
Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet.
Topics: Antiviral Agents; Cells, Cultured; Fluorescent Antibody Technique; Foscarnet; HIV-1; Humans; Organophosphorus Compounds; Phosphonoacetic Acid; Zidovudine | 1989 |
Comparative assessment of antiretrovirals in human monocyte-macrophages and lymphoid cell lines acutely and chronically infected with the human immunodeficiency virus.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Foscarnet; Gene Products, gag; HIV; HIV Antigens; HIV Core Protein p24; Humans; Interferon Type I; Macrophages; Monocytes; Phosphonoacetic Acid; RNA, Viral; Tumor Cells, Cultured; Viral Core Proteins; Virus Replication; Zidovudine | 1989 |
Structure-activity relationships of fluorinated nucleoside analogs and their synergistic effect in combination with phosphonoformate against human immunodeficiency virus type 1.
Topics: Antiviral Agents; Cells, Cultured; Dideoxynucleosides; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Foscarnet; HIV-1; Humans; Phosphonoacetic Acid; Structure-Activity Relationship; Virus Replication; Zidovudine | 1989 |
Foscarnet in the treatment of cytomegalovirus retinitis in acquired immune deficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Creatine; Cytomegalovirus Infections; Drug Therapy, Combination; Female; Foscarnet; Humans; Infusions, Intravenous; Male; Middle Aged; Organophosphorus Compounds; Phosphonoacetic Acid; Retinitis; Time Factors; Visual Acuity; Zidovudine | 1989 |
Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro.
Topics: Antiviral Agents; Cells, Cultured; Cytomegalovirus; DNA-Directed DNA Polymerase; Drug Synergism; Foscarnet; HIV-1; Humans; Monocytes; Organophosphorus Compounds; Phosphonoacetic Acid; Viral Plaque Assay; Virus Replication; Zidovudine | 1989 |
Acyclovir-resistant herpes in AIDS treated with foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Drug Resistance, Microbial; Female; Foscarnet; Herpes Genitalis; Humans; Organophosphorus Compounds; Phosphonoacetic Acid; Simplexvirus; Thymidine; Zidovudine | 1988 |
AIDS: the virus, antivirals and vaccines.
Topics: Acquired Immunodeficiency Syndrome; Antimony; Antiviral Agents; Foscarnet; Genes, Viral; HIV; Humans; Phosphonoacetic Acid; Suramin; Thymidine; Tungsten; Tungsten Compounds; Viral Vaccines; Virus Replication; Zidovudine | 1987 |
Identification of the amino acid in the human immunodeficiency virus type 1 reverse transcriptase involved in the pyrophosphate binding of antiviral nucleoside triphosphate analogs and phosphonoformate. Implications for multiple drug resistance.
Topics: Amino Acids; Antiviral Agents; Binding Sites; Dideoxynucleotides; Diphosphates; Drug Resistance, Microbial; Foscarnet; HIV Reverse Transcriptase; HIV-1; Kinetics; Recombinant Proteins; RNA-Directed DNA Polymerase; Thymine Nucleotides; Zidovudine | 1993 |
Long-term foscarnet therapy not associated with the development of foscarnet-resistant human immunodeficiency virus type 1 in an acquired immunodeficiency syndrome patient.
Topics: Acquired Immunodeficiency Syndrome; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Foscarnet; Herpes Genitalis; Herpesvirus 2, Human; HIV Reverse Transcriptase; HIV-1; Humans; RNA-Directed DNA Polymerase; Time Factors; Zidovudine | 1994 |
Drugs for AIDS and associated infections.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Antiprotozoal Agents; Antiviral Agents; Atovaquone; Candidiasis, Oral; Clindamycin; Clotrimazole; Cryptosporidiosis; Cytomegalovirus Infections; Dapsone; Didanosine; Drug Combinations; Drug Therapy, Combination; Fluconazole; Flucytosine; Folic Acid Antagonists; Foscarnet; Glucuronates; Herpes Simplex; Herpes Zoster; Humans; Isoniazid; Itraconazole; Ketoconazole; Lamivudine; Mycobacterium avium-intracellulare Infection; Naphthoquinones; Nystatin; Pentamidine; Pneumocystis Infections; Pneumonia, Pneumocystis; Prednisone; Primaquine; Reverse Transcriptase Inhibitors; Stavudine; Syphilis; Toxoplasmosis; Trimetrexate; Tuberculosis; Zalcitabine; Zidovudine | 1995 |
Inhibition of HIV-1 replication in H9 cells by nystatin-A compared with other antiviral agents.
Topics: Amphotericin B; Antiviral Agents; Cell Line, Transformed; Cell Survival; Foscarnet; HIV Core Protein p24; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Nystatin; Reverse Transcriptase Inhibitors; Virus Replication; Zidovudine | 1993 |
[Current developments in antiviral chemotherapy. Part 4: Foscarnet, zidovudine, didanosine].
Topics: AIDS-Related Opportunistic Infections; Didanosine; Dose-Response Relationship, Drug; Drug Administration Schedule; Foscarnet; Herpesviridae Infections; HIV Infections; Humans; Zidovudine | 1994 |
Multiple-drug-resistant mutants of feline immunodeficiency virus selected with 2',3'-dideoxyinosine alone and in combination with 3'-azido-3'-deoxythymidine.
Topics: Animals; Antiviral Agents; Cats; Cells, Cultured; Didanosine; Drug Resistance, Microbial; Foscarnet; Immunodeficiency Virus, Feline; Mutation; Phenotype; Zalcitabine; Zidovudine | 1994 |
Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines.
Topics: Antiviral Agents; Arabinonucleosides; Cell Division; Cell Line; Dideoxynucleosides; Dideoxynucleotides; DNA; Drug Interactions; Foscarnet; Humans; Oligonucleotide Probes; Repetitive Sequences, Nucleic Acid; Reverse Transcriptase Inhibitors; Telomerase; Telomere; Thymine Nucleotides; Zidovudine | 1996 |
Antiviral activity of a phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs.
Topics: Antiviral Agents; Base Sequence; Cell Line; Cytomegalovirus; Drug Interactions; Foscarnet; Ganciclovir; HIV-1; Humans; Molecular Sequence Data; Nucleic Acid Synthesis Inhibitors; RNA, Viral; Thionucleotides; Virus Replication; Zalcitabine; Zidovudine | 1995 |
Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cohort Studies; Cytomegalovirus Retinitis; Foscarnet; Ganciclovir; HIV Infections; HIV-1; Humans; Immune Tolerance; Incidence; Male; Pneumonia, Pneumocystis; Prevalence; Survival Rate; Zidovudine | 1996 |
Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine.
Topics: Antiviral Agents; Cells, Cultured; Didanosine; Drug Combinations; Drug Resistance, Microbial; Drug Synergism; Foscarnet; HIV-1; Humans; Microbial Sensitivity Tests; Monocytes; Zalcitabine; Zidovudine | 1996 |
Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet.
Topics: Antiviral Agents; Drug Resistance; Foscarnet; HIV-1; Humans; Molecular Sequence Data; Mutation; Zidovudine | 1996 |
In vivo toxicity of foscarnet and zidovudine given alone or in combination.
Topics: Animals; Antiviral Agents; Female; Foscarnet; Hematologic Diseases; Injections, Intraperitoneal; Kidney; Kidney Diseases; Mice; Mice, Inbred C57BL; Microscopy, Electron; Organelles; Zidovudine | 1996 |
Use of herpes simplex virus thymidine kinase to improve the antiviral activity of zidovudine.
Topics: Animals; Anti-HIV Agents; Cells, Cultured; Foscarnet; Herpesvirus 1, Human; Humans; Lymphocytes; Mice; Monocytes; Phosphorylation; Thymidine Kinase; Virus Replication; Zidovudine | 1997 |
Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates.
Topics: Anti-HIV Agents; Cell Line, Transformed; Cells, Cultured; Didanosine; Foscarnet; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; Zidovudine | 1998 |
Measurement of viral sequences in cerebrospinal fluid of AIDS patients with cerebral white-matter lesions using polymerase chain reaction.
Topics: Adolescent; Adult; AIDS Dementia Complex; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Brain; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Drug Therapy, Combination; Female; Foscarnet; HIV-1; Humans; JC Virus; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Middle Aged; Papillomavirus Infections; Polymerase Chain Reaction; RNA, Viral; Zidovudine | 1998 |
Coresistance to zidovudine and foscarnet is associated with multiple mutations in the human immunodeficiency virus type 1 reverse transcriptase.
Topics: Amino Acid Sequence; Anti-HIV Agents; Drug Resistance; Foscarnet; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Sequence Data; Mutation; Polymerase Chain Reaction; Zidovudine | 1998 |
Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase.
Topics: Catalysis; Diphosphates; DNA, Viral; Drug Resistance, Microbial; Foscarnet; HIV Reverse Transcriptase; HIV-1; Mutagenesis, Site-Directed; Peptide Chain Termination, Translational; Phenotype; Polymers; Protein Processing, Post-Translational; Reverse Transcriptase Inhibitors; Templates, Genetic; Zidovudine | 1998 |
Synthesis and antiviral evaluation of SATE-foscarnet prodrugs and new foscarnet-AZT conjugates.
Topics: Anti-HIV Agents; Antiviral Agents; Cell Line; Foscarnet; Hepatitis B virus; HIV-1; Humans; Magnetic Resonance Spectroscopy; Mass Spectrometry; Microbial Sensitivity Tests; Molecular Structure; Prodrugs; Tumor Cells, Cultured; Zidovudine | 1998 |
Biochemical characterization of HIV-1 reverse transcriptases encoding mutations at amino acid residues 161 and 208 involved in resistance to phosphonoformate.
Topics: Amino Acids; Diphosphates; Dose-Response Relationship, Drug; Drug Resistance; Enzyme Stability; Foscarnet; HIV Reverse Transcriptase; Kinetics; Mutagenesis, Site-Directed; Nevirapine; Recombinant Proteins; Reverse Transcriptase Inhibitors; Zidovudine | 1998 |
Survival differences associated with treatment of cytomegalovirus retinitis in Maryland patients with AIDS, 1987-1994.
Topics: Adult; Age Factors; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Cytomegalovirus Retinitis; Drug Therapy, Combination; Female; Foscarnet; Ganciclovir; Humans; Male; Maryland; Retrospective Studies; Risk Factors; Sex Factors; Zidovudine | 1999 |
Mechanism by which phosphonoformic acid resistance mutations restore 3'-azido-3'-deoxythymidine (AZT) sensitivity to AZT-resistant HIV-1 reverse transcriptase.
Topics: Anti-HIV Agents; Base Sequence; DNA Primers; DNA Replication; Drug Resistance, Microbial; Foscarnet; HIV Reverse Transcriptase; HIV-1; Mutation; Recombinant Proteins; Reverse Transcriptase Inhibitors; Zidovudine | 2000 |
In vitro anti-HIV-1 activity of sn-2-substituted 1-O-octadecyl-sn-glycero-3-phosphonoformate analogues and synergy with zidovudine.
Topics: Antiviral Agents; Drug Carriers; Drug Combinations; Drug Synergism; Foscarnet; HeLa Cells; HIV-1; Humans; Liposomes; Viral Plaque Assay; Virus Replication; Zidovudine | 2000 |
Phosphorylation of AZT-resistant human immunodeficiency virus type 1 reverse transcriptase by casein kinase II in vitro: effects on inhibitor sensitivity.
Topics: Amino Acid Motifs; Amino Acid Sequence; Binding Sites; Casein Kinase II; Consensus Sequence; Dideoxynucleotides; DNA; DNA Repair; Drug Resistance, Microbial; Enzyme Activation; Foscarnet; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Peptide Mapping; Phosphoric Monoester Hydrolases; Phosphorylation; Phosphoserine; Phosphothreonine; Protein Serine-Threonine Kinases; Recombinant Proteins; Reverse Transcriptase Inhibitors; Substrate Specificity; Thymine Nucleotides; Zidovudine | 2000 |
Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistance.
Topics: Drug Resistance, Microbial; Foscarnet; HIV-1; Microbial Sensitivity Tests; Prodrugs; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Virion; Zidovudine | 2001 |
Effectiveness of rescue antiretroviral therapy including intravenously administered zidovudine and foscarnet in a child with HIV-1 enteropathy.
Topics: Anti-HIV Agents; Female; Foscarnet; HIV Enteropathy; HIV-1; Humans; Infant; RNA, Viral; Zidovudine | 2003 |
Relationship between 3'-azido-3'-deoxythymidine resistance and primer unblocking activity in foscarnet-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase.
Topics: Antiviral Agents; Binding Sites; Cell Line; Deoxyadenine Nucleotides; Dideoxynucleotides; Diphosphates; DNA Primers; Drug Resistance, Viral; Foscarnet; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Templates, Genetic; Thymine Nucleotides; Zidovudine | 2003 |
Uncharged AZT and D4T derivatives of phosphonoformic and phosphonoacetic acids as anti-HIV pronucleosides.
Topics: Anti-HIV Agents; Cell Line; Drug Stability; Foscarnet; HIV-1; Humans; Hydrolysis; Phosphonoacetic Acid; Prodrugs; Stavudine; Stereoisomerism; Structure-Activity Relationship; Zidovudine | 2004 |
Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities.
Topics: Anti-HIV Agents; Binding Sites; Butyrates; Catalysis; Dideoxynucleotides; DNA-Directed DNA Polymerase; Drug Combinations; Drug Synergism; Foscarnet; HIV Reverse Transcriptase; Hydrolysis; Kinetics; Nucleic Acid Synthesis Inhibitors; Oxazines; Reverse Transcriptase Inhibitors; Ribonuclease H; Thiophenes; Thymine Nucleotides; Zidovudine | 2005 |
Hypersusceptibility to substrate analogs conferred by mutations in human immunodeficiency virus type 1 reverse transcriptase.
Topics: Amino Acid Motifs; Catalysis; Drug Resistance, Viral; Foscarnet; HeLa Cells; HIV Reverse Transcriptase; HIV-1; Humans; Mutagenesis; Protein Binding; Protein Structure, Tertiary; Reverse Transcriptase Inhibitors; Substrate Specificity; Virus Replication; Zidovudine | 2006 |
Selective excision of chain-terminating nucleotides by HIV-1 reverse transcriptase with phosphonoformate as substrate.
Topics: Antiviral Agents; Binding Sites; Catalysis; Dideoxynucleotides; Foscarnet; HIV Reverse Transcriptase; Reverse Transcriptase Inhibitors; Thymine Nucleotides; Zidovudine | 2006 |
Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.
Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Multiple, Viral; Evolution, Molecular; Foscarnet; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Point Mutation; Reverse Transcriptase Inhibitors; Species Specificity; Thymidine; Time Factors; Zidovudine | 2007 |
Mechanistic basis of zidovudine hypersusceptibility and lamivudine resistance conferred by the deletion of codon 69 in the HIV-1 reverse transcriptase coding region.
Topics: Amino Acid Sequence; Anti-HIV Agents; Codon; Crystallography, X-Ray; Deoxycytosine Nucleotides; DNA, Viral; Drug Resistance, Multiple, Viral; Foscarnet; HIV Infections; HIV Reverse Transcriptase; Humans; Lamivudine; Models, Molecular; Molecular Sequence Data; Mutation; Nucleic Acid Conformation; Protein Conformation; Reverse Transcriptase Inhibitors; Sequence Alignment; Sequence Deletion; Zidovudine | 2008 |
Foscarnet salvage therapy efficacy is associated with the presence of thymidine-associated mutations (TAMs) in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Foscarnet; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors; Salvage Therapy; Stavudine; Thymidine; Treatment Outcome; Zidovudine | 2008 |
Synthesis and in vitro activities of a new antiviral duplex drug linking Zidovudine (AZT) and Foscarnet (PFA) via an octadecylglycerol residue.
Topics: Antiviral Agents; Cross-Linking Reagents; Cytomegalovirus; Drug Interactions; Foscarnet; Glyceryl Ethers; HIV; Humans; Inhibitory Concentration 50; Simplexvirus; Zidovudine | 2009 |
Response to Stegmann s, et Al. [J. Clin. Virol. 47 (1) (2010) 79-81].
Topics: Anti-HIV Agents; Foscarnet; HIV Infections; HIV-2; Humans; Salvage Therapy; Treatment Outcome; Viral Load; Zidovudine | 2010 |
Treatment of HIV-related primary central nervous system lymphoma with AZT high dose, HAART, interleukin-2 and foscarnet in three patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; Central Nervous System Neoplasms; Foscarnet; Humans; Interleukin-2; Lymphoma, AIDS-Related; Male; Zidovudine | 2011 |
Successful treatment of aciclovir and foscarnet resistant Herpes simplex virus lesions with topical imiquimod in patients infected with human immunodeficiency virus type 1.
Topics: Acyclovir; Administration, Topical; Adult; Aminoquinolines; Antiviral Agents; Drug Resistance, Viral; Foscarnet; Herpes Simplex; HIV Infections; HIV-1; Humans; Imiquimod; Lamivudine; Male; Middle Aged; Nelfinavir; Simplexvirus; Zidovudine | 2012 |
Foscarnet, zidovudine and dolutegravir combination efficacy and tolerability for late stage HIV salvage therapy: A case-series experience.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Female; Foscarnet; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; HIV-2; Humans; Kidney; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; RNA, Viral; Salvage Therapy; Viral Load; Zidovudine | 2016 |